Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

Literature DB >> 27627135

Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

Soni Savai Pullamsetti^1,2,3, Rajkumar Savai^1,2,3, Werner Seeger^1,2,3, Elena A Goncharova⁴.

Abstract

Entities: Disease

Mesh：

Year: 2017 PMID： 27627135 PMCID： PMC5803657 DOI： 10.1164/rccm.201606-1226PP

Source DB: PubMed Journal: Am J Respir Crit Care Med ISSN： 1073-449X Impact factor: 21.405

× No keyword cloud information.

130 in total

1. Mitofusin 2 ameliorates aortic remodeling by suppressing ras/raf/ERK pathway and regulating mitochondrial function in vascular smooth muscle cells.

Authors: Zuoguang Wang; Qiuli Niu; Xiaoyun Peng; Mei Li; Ya Liu; Jielin Liu; Shaojun Wen; Yongxiang Wei
Journal: Int J Cardiol Date: 2014-10-22 Impact factor: 4.164

2. Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension.

Authors: Anna R Hemnes; Min Zhao; James West; John H Newman; Stuart Rich; Stephen L Archer; Ivan M Robbins; Timothy S Blackwell; Joy Cogan; James E Loyd; Zhongming Zhao; Christa Gaskill; Christopher Jetter; Jonathan A Kropski; Susan M Majka; Eric D Austin
Journal: Am J Respir Crit Care Med Date: 2016-08-15 Impact factor: 21.405

3. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

Authors: S D Lee; K R Shroyer; N E Markham; C D Cool; N F Voelkel; R M Tuder
Journal: J Clin Invest Date: 1998-03-01 Impact factor: 14.808

4. Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension.

Authors: Yazhini Ravi; Karuppaiyah Selvendiran; Sarath Meduru; Lucas Citro; Shan Naidu; Mahmood Khan; Brian K Rivera; Chittoor B Sai-Sudhakar; Periannan Kuppusamy
Journal: Cell Biochem Biophys Date: 2013-11 Impact factor: 2.194

5. Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

Authors: Hans-Jürgen Seyfarth; Stefan Hammerschmidt; Michael Halank; Petra Neuhaus; Hubert R Wirtz
Journal: Pulm Circ Date: 2013-11-19 Impact factor: 3.017

6. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Authors: M Sean McMurtry; Stephen L Archer; Dario C Altieri; Sebastien Bonnet; Alois Haromy; Gwyneth Harry; Sandra Bonnet; Lakshmi Puttagunta; Evangelos D Michelakis
Journal: J Clin Invest Date: 2005-06 Impact factor: 14.808

7. Clonal analysis of human colorectal tumors.

Authors: E R Fearon; S R Hamilton; B Vogelstein
Journal: Science Date: 1987-10-09 Impact factor: 47.728

8. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors: Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal: Circulation Date: 2013-09-30 Impact factor: 29.690

9. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.

Authors: Lan Zhao; Ali Ashek; Lei Wang; Wei Fang; Swati Dabral; Olivier Dubois; John Cupitt; Soni Savai Pullamsetti; Emanuele Cotroneo; Hazel Jones; Gianpaolo Tomasi; Quang-De Nguyen; Eric O Aboagye; Mona A El-Bahrawy; Gareth Barnes; Luke S Howard; J Simon R Gibbs; Willy Gsell; Jian-Guo He; Martin R Wilkins
Journal: Circulation Date: 2013-07-30 Impact factor: 29.690

Review 10. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

Authors: Andreas C Joerger; Alan R Fersht
Journal: Annu Rev Biochem Date: 2016-05-04 Impact factor: 23.643

56 in total

1. MicroRNA-mediated downregulation of K⁺ channels in pulmonary arterial hypertension.

Authors: Aleksandra Babicheva; Ramon J Ayon; Tengteng Zhao; Jose F Ek Vitorin; Nicole M Pohl; Aya Yamamura; Hisao Yamamura; Brooke A Quinton; Manqing Ba; Linda Wu; Keeley S Ravellette; Shamin Rahimi; Francesca Balistrieri; Angela Harrington; Rebecca R Vanderpool; Patricia A Thistlethwaite; Ayako Makino; Jason X-J Yuan
Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-09-25 Impact factor: 5.464

2. The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors: Mark R Nicolls; Norbert F Voelkel
Journal: Am J Respir Crit Care Med Date: 2017-05-15 Impact factor: 21.405

3. Translational Advances in the Field of Pulmonary Hypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension.

Authors: Mark T Gladwin
Journal: Am J Respir Crit Care Med Date: 2017-01-01 Impact factor: 21.405

Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

1. Mitofusin 2 ameliorates aortic remodeling by suppressing ras/raf/ERK pathway and regulating mitochondrial function in vascular smooth muscle cells.

2. Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension.

3. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

4. Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension.

5. Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

6. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

7. Clonal analysis of human colorectal tumors.

8. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

9. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.

Review 10. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

1. MicroRNA-mediated downregulation of K⁺ channels in pulmonary arterial hypertension.

2. The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

3. Translational Advances in the Field of Pulmonary Hypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension.

4. TWISTed HIF: revisiting smooth muscle HIF-1α signaling in pulmonary hypertension.

5. Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension.

6. Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension.

7. Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension.

Review 8. Perspective: pathobiological paradigms in pulmonary hypertension, time for reappraisal.

Review 9. The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Review 10. Cell Death in the Lung: The Apoptosis-Necroptosis Axis.